Guardion® has signed a Letter of Appointment with Ho Wah Genting Berhad (HWGB) to create a new formula, designed to enhance the immune system. San Diego, California, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc (“Guardion” or the “Company”) (GHSI) announced that Ho Wah Genting Berhad (“HWGB”) a Malaysian company listed on the Malaysian Stock Exchange (Industrial Products sector) has selected Guardion to develop an immune- supportive formula for their consumer base. HWGB has contracted Guardion and its recently acquired subsidiary NutriGuard, to develop a proprietary formula to meet the demands of their customers for an immune-supportive product.

The Company has approximately 85,247,562 common shares currently issued and outstanding. “We are pleased with the participation of our shareholders and are grateful for their continued support,” commented Michael Favish, CEO of Guardion. “Building on this momentum, we expect to increase awareness of our existing products through a robust marketing effort, while working to develop new products to add to our growing portfolio.”

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), a company (i) that has developed medical foods and medical devices in the ocular health marketplace and (ii) that is developing nutraceuticals that the Company believes will provide health benefits to consumers, announced today that it received an initial order from Astramune Sdn Bhd, a subsidiary of Ho Wah Genting Berhad (“HWGB”) (KLSE:9601), a Malaysian company listed on the Malaysian Stock Exchange (Industrial Products sector), for a sample order of its proprietary immuno-supportive formula. Guardion currently anticipates shipping this sample order by June 30, 2020.

--Growing portfolio of synergistic assets and proprietary technologies --Focusing on scalable market opportunities to drive Company’s growth initiatives.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI) announced that it has received approval from the USPTO for additional claims reflected in a new patent for its proprietary medical device, the MapcatSF®. Also, there will be a patent term adjustment for the patent of 307 days.

San Diego, CA , Aug. 15, 2019 -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), today announced the closing of its previously announced.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences company that, among other things, develops, formulates, manufacture and distributes condition-specific medical foods supported by evidence-based protocols, and provides ocular testing, announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Capital Market (“Nasdaq”) notifying the Company that it has been granted an additional 180-day compliance period or until September 14, 2020, to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5550(a)(2) (the “Rule”). If at any time before September 14, 2020, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Rule, and the matter will be closed.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), today announced the closing of its previously announced underwritten public offering of 24,500,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Series B warrants to purchase up to 24,500,000 shares of the Company’s common stock. Each share of common stock or pre-funded warrant was sold together with one Series B warrant to purchase one share of common stock at a combined price to the public of $0.342 per share and warrant.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI) announced today that its immuno-supportive/anti-oxidant complex, labeled acuMMUNETM (trademark registration pending), is now commercially available. As the first Guardion product produced under our NutriGuard label, we are pleased to offer a product designed with the objective of supporting effective immune function.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI) announced the development of a unique proprietary formulation to provide immuno-support and anti-inflammatory benefits targeting the upper respiratory tract. The Company’s efforts are being spearheaded by its recently acquired NutriGuard business line. This proprietary new product, to be preliminarily labeled acuMMUNE (trademark registration pending), was designed by Guardion’s internal product and technology design team, and is the first product to be introduced by Guardion under the NutriGuard label.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), through its newly-formed wholly-owned subsidiary, NutriGuard Formulations, Inc., has acquired certain assets of NutriGuard Research, Inc. (“NutriGuard”). This acquisition, which was effective as of September 20, 2019, provides a direct-to-consumer (“DTC”) capability for the Company. Guardion is a leader in the field of ocular health technologies and products.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), announced the pricing of an underwritten public offering of 24,500,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and Series B warrants to purchase up to 24,500,000 shares of the Company’s common stock. Each share of common stock (or pre-funded warrants to purchase common stock in lieu thereof) is being sold together with one Series B warrant to purchase one share of common stock at a combined price to the public of $0.342 per share and Series B warrant.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI) announced that it has completed development of its proprietary CSV-2000 standardized contrast sensitivity test and will introduce the commercial product at Vision Expo West, a conference for ophthalmic professionals, in Las Vegas, Nevada, from September 18 to 21, 2019. The CSV-2000 is the only computer-generated vision testing instrument available that will provide the optical marketplace with the Company’s proprietary, industry-standard contrast sensitivity test, along with a full suite of standard vision testing protocols. The proprietary standardization methodology incorporated into the CSV-2000 includes a patented technology known as AcQviz that automatically and constantly measures and adjusts screen luminance to a fixed standard light level for vision testing.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), a company that (i) develops medical foods and medical devices in the ocular health marketplace and (ii) is developing nutraceuticals that the Company believes will provide health benefits to consumers, announced today the publication of study data comparing the efficacy of the Company’s micronized liquid formula Lumega-Z®, to the current standard AREDS 2 soft gel supplement. Results from the study concluded that Guardion’s unique, proprietary formulation, Lumega-Z, provided significantly higher blood concentration levels of carotenoids, which have been shown by studies sponsored by the National Eye Institute to be important for slowing the progression of macular degeneration in certain patients, and the MPOD, which has been shown in studies to be an important and modifiable biomarker to track the progression of macular degeneration and other eye diseases.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), a company (i) that has developed medical foods and medical devices in the ocular health marketplace and (ii) that is developing nutraceuticals that the Company believes will provide health benefits to consumers, announced today that Michael Favish, CEO of Guardion Health Sciences, will present at the April 2020 Virtual Investor Summit on Wednesday, April 22nd, 2020 at 1:30 PM Eastern Time. A live audio webcast of the presentation will be available in the News and Events section of the Company’s website (guardionhealth.com).

Results Highlighted by 33% Increase in Revenues for Guardion’s Flagship Medical Food Lumega-Z® San Diego, CA, Nov. 14, 2019 -- Guardion Health Sciences, Inc. (“Guardion” or.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI) announced the formal results of a blood assay study that established that Lumega-Z, Guardion’s proprietary medical food designed specifically to replenish and restore the eye’s macular protective pigment, provided 40 times higher concentrations and bioavailability of mesozeaxanthin in the blood as compared to over-the-counter AREDS2 gel cap supplements. The study was conducted by Professor Richard A. Bone, BSc, PhD, a member of the faculty of the Department of Physics at Florida International University in Miami, Florida. Dr. Bone is also a member of the Company’s Scientific Advisory Board.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), a company that (i) has developed medical foods and medical devices in the ocular health marketplace and (ii) is developing condition-specific nutraceuticals that the Company believes will provide supportive health benefits to consumers, announced today its financial results for the quarter ended March 31, 2020. The Company also provided a corporate update and product overview. While our medical device sales slowed due to doctor office closures as a result of government mandated stay-at-home orders that commenced in March, we were able to offset this by a 40% increase in our medical foods revenue.

Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), a leader in the field of ocular health technologies and products, announced that it has hired John P. Troup, PhD to serve as President of the Company’s NutriGuard business line, which was acquired by the Company effective as of September 20, 2019. The NutriGuard business, with a 30-year operating history, is expected to provide the Company with a direct-to-consumer (“DTC”) capability. The Company’s objective is to develop NutriGuard into a globally-recognized and respected, physician-preferred nutraceuticals brand.